FLT3 and leukemia: Despite the development of FLT3 inhibitors, the EMBT Acute Leukemia Working Party recommends performing ASCT in their 2017-ELN risk stratification, but with the accompaniment of post-transplantation FLT3 inhibitor maintenance for at least 2 years (146).